Excelsior Biopharma Inc. (6496.TWO)
Taipei Exchange · TWD · Healthcare · Drug Manufacturers - Specialty & Generic
NT$23.35 (+0.00%) as of
Key statistics
- Market cap
- 1.09B
- EPS (TTM)
- -4.45
- Dividend yield
- 0.00%
- 52-week range
- 22.50 – 30.55
- Beta
- -0.17
- Revenue (TTM)
- 936.92M
- Profit margin
- -22.05%
- Volume
- 4.98k
About Excelsior Biopharma Inc.
Excelsior Biopharma Inc. develops and sells pharmaceutical products in Taiwan, China, and internationally. It offers general pharmaceuticals; orphan drugs; antidotes; rapid test kits and reagent; consumer products under the Repavar, Om3gafort, Oral7, and Excelsior Probiotics brand names; and over the counter drugs under the Norit, Puresenna, and Tazac brand names. The company also provides specialty medicine and public health products. In addition, it is involved in importing and exporting of active pharmaceutical ingredients, food, and cosmeceuticals; development of cosmetics; research, importing and exporting of technologies; and pharmaceutical technologies transfer. The company was formerly known as Excelsior Enterprise Co., Ltd. and changed its name to Excelsior Biopharma Inc. in June 2003. Excelsior Biopharma Inc. was founded in 1986 and is headquartered in Taipei, Taiwan.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Taipei, Taiwan
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.